{"id":"NCT04712903","sponsor":"AstraZeneca","briefTitle":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","officialTitle":"A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-16","primaryCompletion":"2023-06-21","completion":"2023-06-21","firstPosted":"2021-01-15","resultsPosted":"2025-01-07","lastUpdate":"2025-01-07"},"enrollment":101,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Carcinoma Extensive Disease"],"interventions":[{"type":"DRUG","name":"Durvalumab","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Durvalumab in Combination with Platinum-Etoposide","type":"EXPERIMENTAL"}],"summary":"This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with platinum-etoposide as first-line treatment in Spain.","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs) Grade â‰¥ 3","timeFrame":"During study treatment, until disease progression (median 6 months)","effectByArm":[{"arm":"Experimental Arm","deltaMin":77,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":5},"locations":{"siteCount":34,"countries":["Spain"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00005&amp;attachmentIdentifier=40fa9dfc-24d1-4222-8331-d930c6bb3390&amp;fileName=D419QC00005_CSR_synopsis.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00005&amp;attachmentIdentifier=901bd86a-a64f-4156-a1e8-0ed31672640b&amp;fileName=D419QC00005_SAP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00005&amp;attachmentIdentifier=2bd9ee06-7e52-491e-a204-58779ccf7f98&amp;fileName=D419QC00005_Protocol.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":101},"commonTop":["Asthenia","Anaemia","Neutropenia","Dyspnoea","Constipation"]}}